159 related articles for article (PubMed ID: 7995070)
21. [Effect of lamellar keratoplasty time on the production of serum specific antibody in corneal alkali burns].
Zheng XF; Feng KX; Li B; Yang JZ; Ge JJ
Zhonghua Yan Ke Za Zhi; 2004 Mar; 40(3):160-4. PubMed ID: 15307985
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat.
Juberías JR; Calonge M; Gómez S; López MI; Calvo P; Herreras JM; Alonso MJ
Curr Eye Res; 1998 Jan; 17(1):39-46. PubMed ID: 9472469
[TBL] [Abstract][Full Text] [Related]
23. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits.
Shi W; Gao H; Xie L; Wang S
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3339-44. PubMed ID: 16877400
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of systemic cyclosporine A and amniotic membrane on rabbit conjunctival limbal allograft rejection.
Dios E; Herreras JM; Mayo A; Blanco G
Cornea; 2005 Mar; 24(2):182-8. PubMed ID: 15725887
[TBL] [Abstract][Full Text] [Related]
25. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy.
Hill JC
Ophthalmology; 1994 Jan; 101(1):128-33. PubMed ID: 8302545
[TBL] [Abstract][Full Text] [Related]
26. Preliminary findings in corneal allograft rejection in patients with keratoconus.
Hargrave S; Chu Y; Mendelblatt D; Mayhew E; Niederkorn J
Am J Ophthalmol; 2003 Apr; 135(4):452-60. PubMed ID: 12654360
[TBL] [Abstract][Full Text] [Related]
27. [Sustained rapamycin drug delivery system in prevention of high risk corneal allograft rejection and neovascularization in rabbits].
Gao H; Shi WY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2006 Jan; 42(1):6-11. PubMed ID: 16638273
[TBL] [Abstract][Full Text] [Related]
28. The effect of duration and timing of systemic cyclosporine therapy on corneal allograft survival in a rat model.
Claerhout I; Beele H; Verstraete A; Van den Broecke C; Kestelyn P
Graefes Arch Clin Exp Ophthalmol; 2001 Feb; 239(2):152-7. PubMed ID: 11372546
[TBL] [Abstract][Full Text] [Related]
29. Chemical burn to eye resulting in a heavy vascularized opaque cornea.
Refract Corneal Surg; 1991; 7(5):395-7. PubMed ID: 1958629
[No Abstract] [Full Text] [Related]
30. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of OXB-202, a Genetically Engineered Tissue Therapy for the Prevention of Rejection in High-Risk Corneal Transplant Patients.
Fouladi N; Parker M; Kennedy V; Binley K; McCloskey L; Loader J; Kelleher M; Mitrophanous KA; Stout JT; Ellis S
Hum Gene Ther; 2018 Jun; 29(6):687-698. PubMed ID: 29361840
[TBL] [Abstract][Full Text] [Related]
32. Local therapy of corneal allograft rejection with cyclosporine.
Zhao JC; Jin XY
Am J Ophthalmol; 1995 Feb; 119(2):189-94. PubMed ID: 7832225
[TBL] [Abstract][Full Text] [Related]
33. Suppression of graft rejection using 15-deoxyspergualin in the allogeneic rat penetrating keratoplasty model.
Holland EJ; Olsen TW; Sterrer J; Ketchum JM; Mindrup EA; Gruber SA
Cornea; 1994 Jan; 13(1):28-32. PubMed ID: 8131403
[TBL] [Abstract][Full Text] [Related]
34. [Combined rapamycin eye drop in nanometer vector and poly (lactic acid) wafers of cyclosporine A effectively prevents high-risk corneal allograft rejection in rabbits].
Jiang W; Sun HM; Li XR; Yuan XB; Wang YQ; Zhang SX; Tian EJ; Yuan JQ
Zhonghua Yan Ke Za Zhi; 2009 Jun; 45(6):550-5. PubMed ID: 19957680
[TBL] [Abstract][Full Text] [Related]
35. Rapamycin inhibits corneal allograft rejection and neovascularization.
Olsen TW; Benegas NM; Joplin AC; Evangelista T; Mindrup EA; Holland EJ
Arch Ophthalmol; 1994 Nov; 112(11):1471-5. PubMed ID: 7980138
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction.
Den S; Sotozono C; Kinoshita S; Ikeda T
Acta Ophthalmol Scand; 2004 Apr; 82(2):195-9. PubMed ID: 15043540
[TBL] [Abstract][Full Text] [Related]
37. A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study.
Shi W; Chen M; Xie L; Liu M; Gao H; Wang T; Wu X; Zhao J
Ophthalmology; 2013 Apr; 120(4):695-702. PubMed ID: 23246118
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of subconjunctival cyclosporin-containing microspheres on keratoplasty rejection in the rabbit.
de Rojas Silva MV; Rodríguez-Ares MT; Sánchez-Salorio M; Lamas Díaz MJ; Cuevas Alvarez J; Vila Jato JL; Capeans Tomé C
Graefes Arch Clin Exp Ophthalmol; 1999 Oct; 237(10):840-7. PubMed ID: 10502059
[TBL] [Abstract][Full Text] [Related]
39. Anaylsis of birefringence during wound healing and remodeling following alkali burns in rabbit cornea.
Huang Y; Meek KM; Ho MW; Paterson CA
Exp Eye Res; 2001 Oct; 73(4):521-32. PubMed ID: 11825023
[TBL] [Abstract][Full Text] [Related]
40. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model.
Shi W; Chen M; Xie L
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1691-7. PubMed ID: 17541621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
